These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30548554)

  • 1. Management of local or regional non-nodal disease.
    Racz JM; Block MS; Baum CL; Jakub JW
    J Surg Oncol; 2019 Jan; 119(2):187-199. PubMed ID: 30548554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma: the management of local recurrence and in-transit metastasis.
    Couture J
    Can J Surg; 1982 Nov; 25(6):698-700. PubMed ID: 7139431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-transit melanoma: an individualized approach.
    Grotz TE; Mansfield AS; Kottschade LA; Erickson LA; Otley CC; Markovic SN; Jakub JW
    Oncology (Williston Park); 2011 Dec; 25(14):1340-8. PubMed ID: 22329185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional therapies for in-transit disease.
    Speicher PJ; Meriwether CH; Tyler DS
    Surg Oncol Clin N Am; 2015 Apr; 24(2):309-22. PubMed ID: 25769714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment of locoregional recurrence of melanoma.
    Squires MH; Delman KA
    Curr Oncol Rep; 2013 Oct; 15(5):465-72. PubMed ID: 23907518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of melanoma in-transit metastases confined to the limb.
    Eggermont AM
    Cancer Surv; 1996; 26():335-49. PubMed ID: 8783582
    [No Abstract]   [Full Text] [Related]  

  • 8. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of in-transit melanoma metastases.
    Testori A; Ribero S; Bataille V
    Eur J Surg Oncol; 2017 Mar; 43(3):544-560. PubMed ID: 27923593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional treatment of metastatic melanoma: a review of therapeutic options.
    Weide B; Neri D; Elia G
    Cancer Immunol Immunother; 2017 May; 66(5):647-656. PubMed ID: 28078357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy for unresectable recurrent and in-transit extremity melanoma.
    Gimbel MI; Delman KA; Zager JS
    Cancer Control; 2008 Jul; 15(3):225-32. PubMed ID: 18596674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional non-nodal metastases of cutaneous melanoma.
    Cascinelli N; Bufalino R; Marolda R; Belli F; Nava M; Galluzzo D; Santinami M; Levene A
    Eur J Surg Oncol; 1986 Jun; 12(2):175-80. PubMed ID: 3709823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical treatment options for stage IV melanoma.
    Wei IH; Healy MA; Wong SL
    Surg Clin North Am; 2014 Oct; 94(5):1075-89, ix. PubMed ID: 25245969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of cutaneous malignant melanoma after more than 20 years.
    Bredgaard R; Lock-Andersen J
    J Plast Surg Hand Surg; 2011 Apr; 45(2):113-6. PubMed ID: 21504283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local and intralesional therapy of in-transit melanoma metastases.
    Testori A; Faries MB; Thompson JF; Pennacchioli E; Deroose JP; van Geel AN; Verhoef C; Verrecchia F; Soteldo J
    J Surg Oncol; 2011 Sep; 104(4):391-6. PubMed ID: 21858834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic hyperthermic limb perfusion in stage I melanoma.
    Krige JE; King HS; Strover RM
    Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma: An update on systemic therapies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma.
    Long TH; Shinohara MM; Argenyi ZB; Thompson JA; Gardner JM
    J Cutan Pathol; 2018 Nov; 45(11):864-868. PubMed ID: 30054925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.
    Wright FC; Kellett S; Hong NJL; Sun AY; Hanna TP; Nessim C; Giacomantonio CA; Temple-Oberle CF; Song X; Petrella TM
    Curr Oncol; 2020 Jun; 27(3):e318-e325. PubMed ID: 32669939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.